scholarly journals Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine.

1996 ◽  
Vol 98 (10) ◽  
pp. 2308-2314 ◽  
Author(s):  
D L Kasper ◽  
L C Paoletti ◽  
M R Wessels ◽  
H K Guttormsen ◽  
V J Carey ◽  
...  
Keyword(s):  
Immune Response ◽  
Conjugate Vaccine ◽  
Tetanus Toxoid ◽  
Type Iii ◽  
Streptococcal Polysaccharide ◽  
Group B

scholarly journals Alpha C Protein as a Carrier for Type III Capsular Polysaccharide and as a Protective Protein in Group B Streptococcal Vaccines

1999 ◽  
Vol 67 (5) ◽  
pp. 2491-2496 ◽  
Author(s):  
Claudia Gravekamp ◽  
Dennis L. Kasper ◽  
Lawrence C. Paoletti ◽  
Lawrence C. Madoff
Keyword(s):  
Conjugate Vaccine ◽  
Tetanus Toxoid ◽  
Capsular Polysaccharide ◽  
Protein A ◽  
Surface Protein ◽  
Negative Control ◽  
Group B Streptococci ◽  
C Protein ◽  
Type Iii ◽  
Group B

ABSTRACT The alpha C protein, a protective surface protein of group B streptococci (GBS), is present in most non-type III GBS strains. Conjugate vaccines composed of the alpha C protein and type III capsular polysaccharide (CPS) might be protective against most GBS infections. In this study, the type III CPS was covalently coupled to full-length, nine-repeat alpha C protein (resulting in III-α9r conjugate vaccine) or to two-repeat alpha C protein (resulting in III-α2r conjugate vaccine) by reductive amination. Initial experiments with the III-α9r vaccine showed that it was poorly immunogenic in mice with respect to both vaccine antigens and was suboptimally efficacious in providing protection in mice against challenge with GBS. Therefore, modified vaccination protocols were used with the III-α2r vaccine. Female mice were immunized three times with 0.5, 5, or 20 μg of the III-α2r vaccine with an aluminum hydroxide adjuvant and bred. Ninety-five percent of neonatal mice born to dams immunized with the III-α2r vaccine survived challenge with GBS expressing type III CPS, and 60% survived challenge with GBS expressing wild-type (nine-repeat) alpha C protein; 18 and 17%, respectively, of mice in the negative control groups survived (P, <0.0001). These protection levels did not differ significantly from those obtained with the type III CPS-tetanus toxoid conjugate vaccine and the unconjugated two-repeat alpha C protein, which protected 98 and 58% of neonates from infection with GBS expressing type III CPS or the alpha C protein, respectively. Thus, the two-repeat alpha C protein in the vaccine was immunogenic and simultaneously enhanced the immunogenicity of type III CPS. III-α vaccines may be alternatives to GBS polysaccharide-tetanus toxoid vaccines, eliciting additional antibodies protective against GBS infection.

Dose–response to type V group B streptococcal polysaccharide–tetanus toxoid conjugate vaccine in healthy adults

Vaccine ◽  
2007 ◽  
Vol 25 (1) ◽  
pp. 55-63 ◽  
Author(s):  
Carol J. Baker ◽  
Marcia A. Rench ◽  
Lawrence C. Paoletti ◽  
Morven S. Edwards
Keyword(s):  
Conjugate Vaccine ◽  
Dose Response ◽  
Tetanus Toxoid ◽  
Healthy Adults ◽  
Streptococcal Polysaccharide ◽  
Group B ◽  
Type V

scholarly journals An oligosaccharide-tetanus toxoid conjugate vaccine against type III group B Streptococcus.

1990 ◽  
Vol 265 (30) ◽  
pp. 18278-18283
Author(s):  
L C Paoletti ◽  
D L Kasper ◽  
F Michon ◽  
J DiFabio ◽  
K Holme ◽  
...  
Keyword(s):  
Conjugate Vaccine ◽  
Tetanus Toxoid ◽  
Group B Streptococcus ◽  
Type Iii ◽  
Group B

scholarly journals Structure‐Guided Design of a Group B Streptococcus Type III Synthetic Glycan–Conjugate Vaccine

2020 ◽  
Vol 26 (31) ◽  
pp. 6944-6944 ◽  
Author(s):  
Davide Oldrini ◽  
Linda Bino ◽  
Ana Arda ◽  
Filippo Carboni ◽  
Pedro Henriques ◽  
...  
Keyword(s):  
Conjugate Vaccine ◽  
Group B Streptococcus ◽  
Type Iii ◽  
Group B

Serological and conformational properties of E. coli K92 capsular polysaccharide and its N-propionylated derivative both illustrate that induced antibody does not recognize extended epitopes of polysialic acid: Implications for a comprehensive conjugate vaccine against groups B and C N. meningitidis

2002 ◽  
Vol 80 (8) ◽  
pp. 1055-1063 ◽  
Author(s):  
Robert A Pon ◽  
Nam Huan Khieu ◽  
Qing-Ling Yang ◽  
Jean-Robert Brisson ◽  
Harold J Jennings
Keyword(s):  
Molecular Dynamics ◽  
Immune Response ◽  
Conjugate Vaccine ◽  
Capsular Polysaccharide ◽  
Competitive Inhibition ◽  
Polysialic Acid ◽  
E Coli ◽  
Protective Epitope ◽  
Conformational Properties ◽  
Group B

The capsular polysaccharide of E. coli K92 (K92P) contains elements in common with the capsular polysaccharides of both groups B and C N. meningitidis, and may therefore form the basis of a bivalent vaccine. In an attempt to augment the cross-protective immune response to group B meningococci, the N-acetyl groups of the K92P were replaced by N-propionyl groups (NPrK92P) and conjugated to protein. This strategy had previously been applied with success to the poorly immunogenic capsular polysaccharide of group B meningococcus (GBMP), and the bactericidal epitope was found to be exclusively mimicked by extended helical segments of the NPrGBMP. The NPrK92P-conjugate, in relation to a K92P-conjugate, failed to enhance the response to GBMP but did generate a measurable response to NPrGBMP, but only at the expense of a greatly reduced GCMP response. Despite the presence of an immune response to NPrGBMP, the anti-NPrK92 serum was not bactericidal. Competitive inhibition studies with NPrGBMP oligosaccharides suggested the NPrK92 antibodies could not cross-react with the protective epitope on group B meningococci, as defined by extended helical segments of the NPrGBMP, but only recognized short non-bactericidal NPrGBMP epitopes. This hypothesis was supported from the conformational and molecular dynamics studies of the K92P, which demonstrated a lack of extended conformations that resemble the GBMP extended epitope. Indeed, the conformational properties of the K92P more closely resembled those of the GCMP, thereby explaining the observed moderate cross-protection of the K92P antiserum towards group C meningococci. Thus, on the basis of these results, it can be concluded that K92P, regardless of N-propionyl modification, will not serve as an effective single vaccine component against both groups B and C meningococci.Key words: conjugate vaccine, Neisseria meningitidis, polysialic acid, NMR, molecular dynamics.

scholarly journals Persistence of the immune response two years after vaccination with quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in Asian adolescents

2016 ◽  
Vol 12 (8) ◽  
pp. 2162-2168 ◽  
Author(s):  
Beatriz P. Quiambao ◽  
Hermant Jain ◽  
Ashish Bavdekar ◽  
Anand Prakash Dubey ◽  
Devayani Kolhe ◽  
...  
Keyword(s):  
Immune Response ◽  
Conjugate Vaccine ◽  
Tetanus Toxoid ◽  
Asian Adolescents

scholarly journals Estimation of Group B Streptococcus Type III Polysaccharide-Specific Antibody Concentrations in Human Sera Is Antigen Dependent

1998 ◽  
Vol 66 (12) ◽  
pp. 5848-5853 ◽  
Author(s):  
Reva Bhushan ◽  
Bascom F. Anthony ◽  
Carl E. Frasch
Keyword(s):  
Human Serum Albumin ◽  
Serum Albumin ◽  
Human Serum ◽  
Conjugate Vaccine ◽  
Group B Streptococcus ◽  
Antigenic Specificity ◽  
Enzyme Linked Immunosorbent Assay ◽  
Type Iii ◽  
Human Sera ◽  
Group B

ABSTRACT The presence of immunoglobulin G (IgG) antibodies against group B streptococcus (GBS) type III polysaccharide (PS) has been correlated with protection against GBS disease. The GBS type III PS is structurally similar to the pneumococcal type 14 PS, differing only in the presence of sialic acid residues. Four different preparations of GBS type III PS were evaluated for their specificity in enzyme-linked immunosorbent assay (ELISA): free PS, free PS mixed with methylated human serum albumin (mHSA), PS conjugated to biotin and PS conjugated to human serum albumin. Three groups of human sera were used to evaluate these PS preparations: sera from recipients of a GBS PS vaccine, sera from women receiving a GBS type III PS-tetanus toxoid conjugate vaccine, and sera from nonimmunized healthy women of childbearing age. Estimated antibody concentrations were different depending on the PS preparation used. Using any of the four preparations, we were able to measure ≤0.05 μg of IgG antibody to the GBS type III PS per ml. The specificity of the assay was determined by competitive inhibition with homologous and heterologous PS. The pneumococcal type 14 PS did not inhibit binding of antibody to the native GBS type III PS in sera from adults receiving the GBS PS vaccine or in sera from nonimmunized adults (except serum G9). The pneumococcal type 14 PS inhibited 50% in sera from recipients of GBS type III conjugate vaccine and in serum G9 when GBS type III PS conjugated to biotin or to HSA was used as antigen in ELISA. These data show that free GBS type III PS or PS mixed with mHSA is a sensitive and specific antigen for ELISA and that conjugation can alter the antigenic specificity of a PS.

Sign in / Sign up

Export Citation Format

Share Document